<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Caspian Journal of Internal Medicine</title>
<title_fa></title_fa>
<short_title>Caspian J Intern Med</short_title>
<subject>Medical Sciences</subject>
<web_url>http://caspjim.com</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-6164</journal_id_issn>
<journal_id_issn_online>2008-6172</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.22088/cjim</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1405</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2026</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>17</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Safety and Outcomes of Etoposide as a Substitute for Radiotherapy in Primary mediastinal B-cell lymphoma Treatment</title>
	<subject_fa>Oncology</subject_fa>
	<subject>Oncology</subject>
	<content_type_fa>Original Article</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;span style=&quot;line-height:150%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; times=&quot;&quot;&gt;&lt;span style=&quot;color:#0033ff;&quot;&gt;&lt;em&gt;&lt;strong&gt;Background:&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt; Primary mediastinal B-cell lymphoma (PMBCL) is a unique subtype of diffuse large B-cell lymphoma. There are some concerns regarding the long-term toxicity of radiotherapy treatment. We compared clinical outcomes and recorded adverse events between DA-EPOCH-R without planned radiotherapy and R-CHOP followed by mediastinal consolidation.&lt;span style=&quot;color:#d86dcb&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;line-height:150%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; times=&quot;&quot;&gt;&lt;span style=&quot;color:#0033ff;&quot;&gt;&lt;em&gt;&lt;strong&gt;Methods:&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt; Medical records of 91 adults with PMBCL treated at Dr. Masih Daneshvari Hospital between 2019 and 2024 were retrospectively reviewed. Forty-six patients received DA-EPOCH-R without planned radiotherapy, whereas 45 received R-CHOP followed by mediastinal radiotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were three-year overall survival (OS), complete metabolic response (CMR), defined as a Deauville score of 1&amp;ndash;3 on PET-CT performed three months after treatment completion, and documented adverse events. &lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;line-height:150%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; times=&quot;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color:#0033ff;&quot;&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/span&gt;&lt;/strong&gt; Median PFS was 12 months in the DA-EPOCH-R group and 13 months in the R-CHOP plus radiotherapy group (log-rank p=0.808). Treatment regimen was unrelated to PFS after adjustment for age and sex (adjusted HR, 1.03; 95% CI, 0.66&amp;ndash;1.61; p=0.884).Three-year OS was 91.3% versus 93.3% (p=0.716), and CMR rates were 87.0% versus 95.6% (p=0.148), respectively. Fever and neutropenia were less frequently documented in the DA-EPOCH-R group (p=0.019 and p=0.001, respectively).&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;line-height:150%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; times=&quot;&quot;&gt;&lt;span style=&quot;color:#0033ff;&quot;&gt;&lt;em&gt;&lt;strong&gt;Conclusion:&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt; &amp;nbsp;PFS, three-year OS, and CMR did not differ significantly between the treatment strategies. Fever and neutropenia were less frequently documented with DA-EPOCH-R.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Primary Mediastinal Large B-Cell Lymphoma, Etoposide, Radiotherapy, R-CHOP Protocol, Progression-Free Survival</keyword>
	<start_page>16</start_page>
	<end_page>0</end_page>
	<web_url>http://caspjim.com/browse.php?a_code=A-10-3976-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Maryam</first_name>
	<middle_name></middle_name>
	<last_name>Salimi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>drmaryamsalimi152245@gmail.com</email>
	<code></code>
	<orcid>0000-0002-7833-978X</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Hematology and Oncology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Babak</first_name>
	<middle_name></middle_name>
	<last_name>Salimi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Babak_salmd@yahoo.com</email>
	<code></code>
	<orcid>0000-0002-5541-8434</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Hamid</first_name>
	<middle_name></middle_name>
	<last_name>Rezvani</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>hamrezvan@sbmu.ac.ir</email>
	<code></code>
	<orcid>0000-0002-8842-6422</orcid>
	<coreauthor>No</coreauthor>
	<affiliation> Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mehdi</first_name>
	<middle_name></middle_name>
	<last_name>Pourghasemian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>m.pourghasemian@gmail.com</email>
	<code></code>
	<orcid>0000-0002-1540-1400</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Ardabil University of Medical Sciences, Ardabil, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Ehsan</first_name>
	<middle_name></middle_name>
	<last_name>Beyramzadeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>debeirami@yahoo.com</email>
	<code></code>
	<orcid>0009-0004-9147-251X</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Hematology and Oncology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad Hossein</first_name>
	<middle_name></middle_name>
	<last_name>Mirzaei</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>M_h.mirzaei@yahoo.com</email>
	<code></code>
	<orcid>0000-0001-7005-1880</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Visveswarapura Institute of Pharmaceutical Sciences, Rajiv Gandhi University of Health Sciences, Bangalore, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Sina</first_name>
	<middle_name></middle_name>
	<last_name>Salari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>salari.sina52@gmail.com</email>
	<code></code>
	<orcid>0000-0001-8298-2578</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation> Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
